MENU
+Compare
INAB
Stock ticker: NASDAQ
AS OF
Apr 3, 04:59 PM (EDT)
Price
$0.16
Change
-$0.01 (-5.88%)
Capitalization
13.86M

INAB IN8bio Forecast, Technical & Fundamental Analysis

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells... Show more

INAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for INAB with price predictions
Apr 02, 2025

INAB in downward trend: 10-day moving average crossed below 50-day moving average on February 27, 2025

The 10-day moving average for INAB crossed bearishly below the 50-day moving average on February 27, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for INAB entered a downward trend on April 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INAB advanced for three days, in of 147 cases, the price rose further within the following month. The odds of a continued upward trend are .

INAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.957) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.036).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
INAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

INAB is expected to report earnings to fall 9.38% to -7 cents per share on May 08

IN8bio INAB Stock Earnings Reports
Q1'25
Est.
$-0.07
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.02
Q2'24
Missed
by $0.02
Q1'24
Missed
by $0.03
The last earnings report on March 13 showed earnings per share of -7 cents, missing the estimate of -7 cents. With 771.00K shares outstanding, the current market capitalization sits at 13.86M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
350 5th Avenue
Phone
+1 646 600-6438
Employees
31
Web
https://www.in8bio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FLL4.240.08
+1.92%
Full House Resorts
CRIS1.480.02
+1.37%
Curis
JOE47.140.59
+1.27%
St Joe Company
EVRI13.720.01
+0.07%
Everi Holdings
K82.45-0.05
-0.06%
Kellanova

INAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, INAB has been loosely correlated with IDYA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if INAB jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INAB
1D Price
Change %
INAB100%
-1.22%
IDYA - INAB
47%
Loosely correlated
+10.70%
GRI - INAB
37%
Loosely correlated
-17.33%
SNSE - INAB
33%
Loosely correlated
+6.09%
CUE - INAB
30%
Poorly correlated
+5.35%
SRZN - INAB
28%
Poorly correlated
+6.65%
More